Gabriella Captur1, Luis R Lopes1, Timothy J Mohun1, Vimal Patel1, Chunming Li1, Paul Bassett1, Gherardo Finocchiaro1, Vanessa M Ferreira1, Maite Tome Esteban1, Vivek Muthurangu1, Mark V Sherrid1, Sharlene M Day1, Charles E Canter1, William J McKenna1, Christine E Seidman1, David A Bluemke1, Perry M Elliott1, Carolyn Y Ho1, James C Moon2. 1. From the Department of Cardiovascular Science (G.C., L.R.L., V.P., V.M., W.J.M., P.M.E., J.C.M.) and Biostatistics Joint Research Office (P.B.), University College London, London, United Kingdom; Department of Inherited Cardiovascular Diseases (G.C., L.R.L., V.P., M.T.E., W.J.M., P.M.E., J.C.M.) and Cardiac Imaging Department (G.C., G.F., M.T.E., W.J.M., J.C.M.), Barts Heart Centre, London, United Kingdom; Department of Developmental Biology, MRC National Institutes for Medical Research, Mill Hill, United Kingdom (T.J.M.); Department of Radiology, University of Pennsylvania, Philadelphia (C.L.); Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford Center for Clinical Magnetic Resonance Research (OCMR), Oxford, United Kingdom (V.M.F.); UCL Department for Cardiovascular Imaging, Great Ormond Street Hospital for Children, London, United Kingdom (V.M.); Department of Cardiology, Mount Sinai Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, New York, NY (M.V.S.); Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor (S.M.D.); Pediatric Cardiology Department, Washington University School of Medicine, St Louis, MO (C.E.C.); Department of Genetics, Harvard Medical School, Boston, MA (C.E.S.); Radiology and Imaging Sciences Department, National Institutes of Health/Clinical Center, Bethesda, MD (D.A.B.); and Cardiovascular Department, Brigham and Women's Hospital, Boston, MA (C.Y.H.). 2. From the Department of Cardiovascular Science (G.C., L.R.L., V.P., V.M., W.J.M., P.M.E., J.C.M.) and Biostatistics Joint Research Office (P.B.), University College London, London, United Kingdom; Department of Inherited Cardiovascular Diseases (G.C., L.R.L., V.P., M.T.E., W.J.M., P.M.E., J.C.M.) and Cardiac Imaging Department (G.C., G.F., M.T.E., W.J.M., J.C.M.), Barts Heart Centre, London, United Kingdom; Department of Developmental Biology, MRC National Institutes for Medical Research, Mill Hill, United Kingdom (T.J.M.); Department of Radiology, University of Pennsylvania, Philadelphia (C.L.); Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford Center for Clinical Magnetic Resonance Research (OCMR), Oxford, United Kingdom (V.M.F.); UCL Department for Cardiovascular Imaging, Great Ormond Street Hospital for Children, London, United Kingdom (V.M.); Department of Cardiology, Mount Sinai Roosevelt Hospital, Icahn School of Medicine at Mount Sinai, New York, NY (M.V.S.); Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor (S.M.D.); Pediatric Cardiology Department, Washington University School of Medicine, St Louis, MO (C.E.C.); Department of Genetics, Harvard Medical School, Boston, MA (C.E.S.); Radiology and Imaging Sciences Department, National Institutes of Health/Clinical Center, Bethesda, MD (D.A.B.); and Cardiovascular Department, Brigham and Women's Hospital, Boston, MA (C.Y.H.). j.moon@ucl.ac.uk.
Abstract
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH). We have proposed that myocardial crypts are part of this phenotype and independently associated with the presence of sarcomere gene mutations. We tested this hypothesis in genetic hypertrophic cardiomyopathy pre-LVH (genotype positive, LVH negative [G+LVH-]). METHODS AND RESULTS: A multicenter case-control study investigated crypts and 22 other cardiovascular magnetic resonance parameters in subclinical hypertrophic cardiomyopathy to determine their strength of association with sarcomere gene mutation carriage. The G+LVH- sample (n=73) was 29 ± 13 years old and 51% were men. Crypts were related to the presence of sarcomere mutations (for ≥1 crypt, β=2.5; 95% confidence interval [CI], 0.5-4.4; P=0.014 and for ≥2 crypts, β=3.0; 95% CI, 0.8-7.9; P=0.004). In combination with 3 other parameters: anterior mitral valve leaflet elongation (β=2.1; 95% CI, 1.7-3.1; P<0.001), abnormal LV apical trabeculae (β=1.6; 95% CI, 0.8-2.5; P<0.001), and smaller LV end-systolic volumes (β=1.4; 95% CI, 0.5-2.3; P=0.001), multiple crypts indicated the presence of sarcomere gene mutations with 80% accuracy and an area under the curve of 0.85 (95% CI, 0.8-0.9). In this G+LVH- population, cardiac myosin-binding protein C mutation carriers had twice the prevalence of crypts when compared with the other combined mutations (47 versus 23%; odds ratio, 2.9; 95% CI, 1.1-7.9; P=0.045). CONCLUSIONS: The subclinical hypertrophic cardiomyopathy phenotype measured by cardiovascular magnetic resonance in a multicenter environment and consisting of crypts (particularly multiple), anterior mitral valve leaflet elongation, abnormal trabeculae, and smaller LV systolic cavity is indicative of the presence of sarcomere gene mutations and highlights the need for further study.
BACKGROUND: Sarcomere protein mutations in hypertrophic cardiomyopathy induce subtle cardiac structural changes before the development of left ventricular hypertrophy (LVH). We have proposed that myocardial crypts are part of this phenotype and independently associated with the presence of sarcomere gene mutations. We tested this hypothesis in genetic hypertrophic cardiomyopathy pre-LVH (genotype positive, LVH negative [G+LVH-]). METHODS AND RESULTS: A multicenter case-control study investigated crypts and 22 other cardiovascular magnetic resonance parameters in subclinical hypertrophic cardiomyopathy to determine their strength of association with sarcomere gene mutation carriage. The G+LVH- sample (n=73) was 29 ± 13 years old and 51% were men. Crypts were related to the presence of sarcomere mutations (for ≥1 crypt, β=2.5; 95% confidence interval [CI], 0.5-4.4; P=0.014 and for ≥2 crypts, β=3.0; 95% CI, 0.8-7.9; P=0.004). In combination with 3 other parameters: anterior mitral valve leaflet elongation (β=2.1; 95% CI, 1.7-3.1; P<0.001), abnormal LV apical trabeculae (β=1.6; 95% CI, 0.8-2.5; P<0.001), and smaller LV end-systolic volumes (β=1.4; 95% CI, 0.5-2.3; P=0.001), multiple crypts indicated the presence of sarcomere gene mutations with 80% accuracy and an area under the curve of 0.85 (95% CI, 0.8-0.9). In this G+LVH- population, cardiac myosin-binding protein C mutation carriers had twice the prevalence of crypts when compared with the other combined mutations (47 versus 23%; odds ratio, 2.9; 95% CI, 1.1-7.9; P=0.045). CONCLUSIONS: The subclinical hypertrophic cardiomyopathy phenotype measured by cardiovascular magnetic resonance in a multicenter environment and consisting of crypts (particularly multiple), anterior mitral valve leaflet elongation, abnormal trabeculae, and smaller LV systolic cavity is indicative of the presence of sarcomere gene mutations and highlights the need for further study.
Authors: Sabe De; Allen G Borowski; Heng Wang; Leah Nye; Baozhong Xin; James D Thomas; W H Wilson Tang Journal: Am Heart J Date: 2011-07-18 Impact factor: 4.749
Authors: Wessel P Brouwer; Tjeerd Germans; Maaike C Head; Jolanda van der Velden; Martijn W Heymans; Imke Christiaans; Arjan C Houweling; Arthur A Wilde; Albert C van Rossum Journal: Eur Heart J Cardiovasc Imaging Date: 2012-01-24 Impact factor: 6.875
Authors: Martin S Maron; Iacopo Olivotto; Caitlin Harrigan; Evan Appelbaum; C Michael Gibson; John R Lesser; Tammy S Haas; James E Udelson; Warren J Manning; Barry J Maron Journal: Circulation Date: 2011-06-13 Impact factor: 29.690
Authors: Philippe Charron; Michael Arad; Eloisa Arbustini; Cristina Basso; Zofia Bilinska; Perry Elliott; Tiina Helio; Andre Keren; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Andreas Perrot; Claudio Rapezzi; Arsen Ristic; Hubert Seggewiss; Irene van Langen; Luigi Tavazzi Journal: Eur Heart J Date: 2010-09-07 Impact factor: 29.983
Authors: Paal Skytt Andersen; Ole Havndrup; Lotte Hougs; Karina M Sørensen; Morten Jensen; Lars Allan Larsen; Paula Hedley; Alex Rojas Bie Thomsen; Johanna Moolman-Smook; Michael Christiansen; Henning Bundgaard Journal: Hum Mutat Date: 2009-03 Impact factor: 4.878
Authors: Martin S Maron; Ethan J Rowin; David Lin; Evan Appelbaum; Raymond H Chan; C Michael Gibson; John R Lesser; Jana Lindberg; Tammy S Haas; James E Udelson; Warren J Manning; Barry J Maron Journal: Circ Cardiovasc Imaging Date: 2012-05-04 Impact factor: 7.792
Authors: Christopher M Kramer; Jorg Barkhausen; Scott D Flamm; Raymond J Kim; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2008-07-07 Impact factor: 5.364
Authors: John D Groarke; Patrycja Z Galazka; Allison L Cirino; Neal K Lakdawala; Jens J Thune; Henning Bundgaard; E John Orav; Robert A Levine; Carolyn Y Ho Journal: Eur Heart J Cardiovasc Imaging Date: 2018-10-01 Impact factor: 6.875
Authors: Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier Journal: Cardiovasc Res Date: 2015-01-28 Impact factor: 10.787
Authors: Carolyn Y Ho; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John L Jefferies; Anne M Murphy; Allison L Cirino; Theodore P Abraham; Matthew Taylor; Luisa Mestroni; David A Bluemke; Petr Jarolim; Ling Shi; Lynn A Sleeper; Christine E Seidman; E John Orav Journal: JAMA Cardiol Date: 2017-04-01 Impact factor: 14.676
Authors: Gabriella Captur; Wendy E Heywood; Caroline Coats; Stefania Rosmini; Vimal Patel; Luis R Lopes; Richard Collis; Nina Patel; Petros Syrris; Paul Bassett; Ben O'Brien; James C Moon; Perry M Elliott; Kevin Mills Journal: Mol Cell Proteomics Date: 2019-06-26 Impact factor: 5.911
Authors: Gabriella Captur; Audrey L Karperien; Alun D Hughes; Darrel P Francis; James C Moon Journal: Nat Rev Cardiol Date: 2016-10-06 Impact factor: 32.419